New drug cocktail shows promise in advanced lung cancer trial
NCT ID NCT05664971
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new experimental drug called JS004, combined with another immunotherapy (toripalimab) and standard chemotherapy, in 119 people with advanced lung cancer. The goal was to see if the combination is safe and might help shrink tumors. The trial has finished, but results are not yet available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
JS004 (anti-BTLA antibody) combined with toripalimab and standard chemotherapy
What this could lead to
If successful, this combination could offer a new treatment option for advanced lung cancer patients who have limited choices.
What could go wrong
This is an early-phase trial (phase 1/2) focused on safety and dosing, so it is too soon to know if it works. Side effects from the immune-based drugs and chemotherapy are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, 200030, China